Compounds > bradykinin, des-phe(8)-des-arg(9)-
Page last updated: 2024-12-08
bradykinin, des-phe(8)-des-arg(9)-
Description
bradykinin, des-Phe(8)-des-Arg(9)-: RN given refers to parent cpd (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
Synonyms (30)
| Synonym |
|---|
| bradykinin, des-phe(8)-des-arg(9)- |
| arg-pro-pro-gly-phe-ser-pro |
| 23815-87-4 |
| 8-des-phe-9-des-arg-bk |
| des-phe8-arg9-bk |
| bradykinin 1-7 |
| des-phe(8)-arg(9)-bk |
| bradykinin (1-7) |
| CHEBI:149658 |
| des-phenylalanyl(8)-des-arginine(9)-bradykinin |
| des-8,9-bk |
| l-arg-l-pro-l-pro-gly-l-phe-l-ser-l-pro |
| r-p-p-g-f-s-p |
| rppgfsp |
| h-arg-pro-pro-gly-phe-ser-pro-oh |
| bk 1-7 |
| bradykinin-(1-7) |
| l-arginyl-l-prolyl-l-prolylglycyl-l-phenylalanyl-l-seryl-l-proline |
| (2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-1-[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid |
| 8-de-phe-9-de-arg-bradykinin |
| bradykinin, des-phenylalanyl(8)-des-arginine(9)- |
| bradykinin, 8-de(l-phenylalanine)-9-de-l-arginine- |
| AS-57945 |
| AKOS030622986 |
| 1-7-bradykinin |
| (s)-1-((s)-2-((s)-2-(2-((s)-1-((s)-1-((s)-2-amino-5-guanidinopentanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamido)acetamido)-3-phenylpropanamido)-3-hydroxypropanoyl)pyrrolidine-2-carboxylic acid |
| CS-0044423 |
| HY-P1484 |
| DTXSID30946609 |
| n-(2-{[2-({[1-(arginylprolyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxyethylidene]amino}-1-hydroxy-3-phenylpropylidene)serylproline |
Roles (2)
| Role | Description |
|---|
| human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
| rat metabolite | Any mammalian metabolite produced during a metabolic reaction in rat (Rattus norvegicus). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
| Class | Description |
|---|
| oligopeptide | A peptide containing a relatively small number of amino acids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.51
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.51 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.31 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |